Home
>
US Stocks
>
BOLT BIOTHERAPEUTICS INC

BOLT BIOTHERAPEUTICS INC (BOLT)

$1.72

-0.11

(-6.01%)▲

Live

Insights on BOLT BIOTHERAPEUTICS INC

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.41M → 1.82M (in $), with an average increase of 22.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 6 quarters, -27.15M → -15.54M (in $), with an average increase of 12.2% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 35.1%

Performance

  • $1.71
    $1.84
    $1.72
    downward going graph

    0.58%

    Downside

    Day's Volatility :7.06%

    Upside

    6.52%

    downward going graph
  • $1.18
    $2.72
    $1.72
    downward going graph

    31.4%

    Downside

    52 Weeks Volatility :56.62%

    Upside

    36.76%

    downward going graph

Returns

PeriodBOLT BIOTHERAPEUTICS INCSector (Health Care)Index (Russel 2000)
3 Months
13.66%
0.3%
-6.7%
6 Months
23.65%
-8.3%
-6.2%
1 Year
7.65%
-4.8%
-6.3%
3 Years
-94.31%
23.8%
26.9%

Highlights

Market Capitalization
69.2M
Book Value
$4.17
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.15
Wall Street Target Price
5.17
Profit Margin
0.0%
Operating Margin TTM
-1258.68%
Return On Assets TTM
-21.69%
Return On Equity TTM
-42.17%
Revenue TTM
6.7M
Revenue Per Share TTM
0.18
Quarterly Revenue Growth YOY
124.6%
Gross Profit TTM
1.6M
EBITDA
-83.1M
Diluted Eps TTM
-2.15
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.86
EPS Estimate Next Year
-1.63
EPS Estimate Current Quarter
-0.46
EPS Estimate Next Quarter
-0.49

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for BOLT BIOTHERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 200.58%

Current $1.72
Target $5.17

Technicals Summary

Sell

Neutral

Buy

BOLT BIOTHERAPEUTICS INC is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
BOLT BIOTHERAPEUTICS INC
BOLT BIOTHERAPEUTICS INC
17.31%
23.65%
7.65%
-94.31%
-94.31%
Moderna, Inc.
Moderna, Inc.
-5.37%
-28.24%
-13.14%
103.02%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.12%
-3.55%
9.07%
20.95%
140.97%
Seagen, Inc.
Seagen, Inc.
-2.85%
59.4%
42.61%
21.68%
240.77%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.3%
22.83%
15.12%
110.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
BOLT BIOTHERAPEUTICS INC
BOLT BIOTHERAPEUTICS INC
NA
NA
NA
-1.86
-0.42
-0.22
0.0
4.17
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.83
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
BOLT BIOTHERAPEUTICS INC
BOLT BIOTHERAPEUTICS INC
Buy
$69.2M
-94.31%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
578.71%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
140.97%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
240.77%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
110.67%
26.53
35.4%

Institutional Holdings

  • Vivo Capital, LLC

    10.24%

  • Sofinnova Ventures

    7.28%

  • Citadel Advisors Llc

    7.28%

  • Pivotal bioVenture Partners Investment Advisor LLC

    5.00%

  • Newtyn Management LLC

    3.04%

  • Samsara BioCapital, LLC

    2.77%

Corporate Announcements

  • BOLT BIOTHERAPEUTICS INC Earnings

    BOLT BIOTHERAPEUTICS INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach combines an antibody that targets a tumor antigen with an immune stimulant that triggers an innate and adaptive immune response in the tumor microenvironment. These systemically-delivered Boltbody ISACs are designed to target tumor cells for elimination by myeloid cells, which are then activated and recruit the adaptive immune system in the anti-tumor response. This leads to the conversion of immunologically "cold" tumors to "hot" tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and a pipeline of other immuno-oncology products.

Organization
BOLT BIOTHERAPEUTICS INC
Employees
94
CEO
Dr. Randall C. Schatzman Ph.D.
Industry
Healthcare

Discover More

FAQs